Six minutes of high-intensity exercise might prolong the lifespan of a healthy brain, perhaps delaying the start of Alzheimer's and Parkinson’s diseases, a new, small study suggests.
The U.S. Food and Drug Administration on Friday approved a second Alzheimer's drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients.
Researchers are studying whether deep brain stimulation could help people with Alzheimer's hold on to their memory longer, and now a new finding may help refine the approach.
The genetic abnormality that drives Down syndrome causes the same sort of abnormal brain plaques and protein tangles that are found in Alzheimer's disease patients, a new study reports.
The experimental Alzheimer's drug lecanemab slowed thinking declines among patients suffering the early stages of the disease in a new study, but safety concerns about brain swelling and brain bleeds remain.
